Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cognition TherapeuticsCGTX -1.31%32 3-Year EBITDA Growth Rate is 29.10% as of Jun. 2026. GuruFocus rates CGTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Cognition Therapeutics ranks better than 65.84% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cognition Therapeutics was 29.10% per year. The lowest was -72.20% per year. And the median was -9.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cognition Therapeutics 3-Year EBITDA Growth Rate Related Terms
CGTX vs RANI, VRCA, YARW: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Cognition Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cognition Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cognition Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.10% mean?
Cognition Therapeutics (CGTX) has a 3-Year EBITDA Growth Rate of 29.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cognition Therapeutics and its competitors. According to the industry distribution chart, Cognition Therapeutics ranks #385 out of 1127 companies in the Biotechnology industry, placing it in the top 34.2%.
Is Cognition Therapeutics' 3-Year EBITDA Growth Rate too high?
Cognition Therapeutics' current 3-Year EBITDA Growth Rate is 29.10%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Cognition Therapeutics' value of 29.10% is 99.3% above this industry median. Based on the distribution chart, Cognition Therapeutics ranks #385 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cognition Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cognition Therapeutics' 3-Year EBITDA Growth Rate compare to RANI and VRCA?
According to the Biotechnology industry distribution chart, Cognition Therapeutics ranks #385 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Cognition Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Cognition Therapeutics' value of 29.10% is 99.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cognition Therapeutics's current 3-Year EBITDA Growth Rate of 29.10% is 99.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cognition Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cognition Therapeutics's current 3-Year EBITDA Growth Rate is 29.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cognition Therapeutics stock overvalued right now?
Cognition Therapeutics (CGTX) has a current 3-Year EBITDA Growth Rate of 29.10%. The current 3-Year EBITDA Growth Rate is 29.10% and 99.3% above the Biotechnology industry median of 14.60. Cognition Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cognition Therapeutics (CGTX), the current 3-Year EBITDA Growth Rate is 29.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
32GF Score
Get the complete analysis for CGTX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGTX has been successfully added to your 
